Efficacy and safety of larotrectinib in neurotrophic tyrosine receptor kinase fusion-positive solid tumors: A multicenter retrospective cohort study in Korea

被引：0

作者：

Lee, S. ^{[1
]}

Yoon, S. ^{[2
]}

Choi, W. ^{[3
]}

Jung, H. A. ^{[4
]}

Bae, S. B. ^{[5
]}

Kim, C. G. ^{[6
]}

Kim, H. R. ^{[7
]}

Lee, K-w. ^{[8
,14
]}

Kang, E. J. ^{[9
]}

Shin, K. ^{[10
,11
]}

Lim, D-j. ^{[12
]}

Kim, . s.

Park, S. ^{[13
]}

Lee, K-e.

Lee, Y. ^{[15
]}

Kim, H. S. ^{[16
]}

Kim, T. J. ^{[17
]}

Kim, M. J. ^{[18
]}

Kang, J. H. ^{[19
]}

机构：

[1] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Div Med Oncol,Dept Internal Med, Seoul, South Korea

[2] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[3] Ctr Clin Trials, Natl Canc Ctr, NCC, Goyang, South Korea

[4] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr SMC, Div Hematol Oncol,Sch Med, Seoul, South Korea

[5] Soonchunhyang Univ Hosp, Dept Internal Med, Div Hematooncol, Cheonan, South Korea

[6] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea

[7] Yonsei Univ, Med Oncol Dept, Yonsei Canc Ctr, Seoul, South Korea

[8] Seoul Natl Univ, Internal Med Dept, Bundang Hosp, Seongnam, South Korea

[9] Korea Univ, Guro Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[10] Catholic Univ Korea, Internal Med Dept, Seoul, South Korea

[11] Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

[12] Catholic Univ Korea, Seoul St Marys Hosp, Endocrinol, Seoul, South Korea

[13] Samsung Med Ctr SMC, Hematol & Med Oncol, Seoul, South Korea

[14] Ewha Womans Univ, Mokdong Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea

[15] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[16] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[17] Catholic Univ Korea, Dept Hosp Pathol, Yeouido St Marys Hosp, Coll Med, Seoul, South Korea

[18] Catholic Univ Korea, Dept Hosp Pathol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea

[19] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Med Ctr, Med Oncol Dept, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

492P

引用

页数：2

共 50 条

[31] Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
Tan, D.
Farago, A.
Kummar, S.
Moreno, V.
Patel, J.
Lassen, U.
Solomon, B.
Rosen, L.
Leyvraz, S.
Reeves, J.
Brega, N.
Dima, L.
Childs, B.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S176 - S176
[32] Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Brose, M. S.
Shen, L.
Tan, D. S. W.
Kummar, S.
Lin, J. J.
McDermott, R.
Berlin, J.
Tahara, M.
Lassen, U. N.
Leyvraz, S.
Patel, J. D.
Norenberg, R.
Dima, L.
Brega, N.
Hong, D. S.
Drilon, A.
ANNALS OF ONCOLOGY, 2021, 32 : S600 - S601
[33] Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
Drilon, A.
Moreno, V.
Patel, J.
Lassen, U.
Solomon, B.
Rosen, L.
Leyvraz, S.
Tan, D. S. W.
Reeves, J. A.
Dima, L.
Brega, N.
Kummar, S.
Farago, A. F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S30 - S31
[34] Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TKR) fusion tumors
Leyvraz, S.
Drilon, A.
Van Tilburg, C. M.
Doz, F.
Kummar, S.
Lin, J. J.
McDermott, R.
Norenberg, R.
Fellous, M.
Brega, N.
Xu, R.
Laetsch, T. W.
Shen, L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 214 - 215
[35] A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
Forsythe, Anna
Zhang, Wei
Phillip Strauss, Uwe
Fellous, Marc
Korei, Maesumeh
Keating, Karen
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[36] Impact of disease evolution on efficacy outcomes from larotrectinib in an ad hoc pooled analysis of patients (Pts) with locally Advanced or Metastatic (Adv/Met) Tropomyosin Receptor Kinase (TRK) fusion-positive solid tumors
Bokemeyer, C.
Vassal, G.
Italiano, A.
De La Cuesta, E.
Hiemeyer, F.
Fellous, M.
Marian, M.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 250 - 251
[37] Larotrectinib: A Novel Tumor-Agnostic Neurotrophic Tropomyosin Receptor Kinase (NTRK) Inhibitor in Advanced Solid Tumors
Dhanushkodi, Manikandan
Bajpai, Jyoti
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (03) : 279 - 281
[38] ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION SOLID TUMORS
Tabatabai, Ghazaleh
Trent, Jonathan
Novello, Silvia
Passiglia, Francesco
Burcoveanu, Domnita-Ileana
Norenberg, Ricarda
Laetsch, Theodore
NEURO-ONCOLOGY, 2023, 25
[39] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Liu, Dazhi
Offin, Michael
Harnicar, Stephen
Li, Bob T.
Drilon, Alexander
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252
[40] EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
Perreault, Sebastien
Doz, Francois
Geoerger, Birgit
Italiano, Antoine
Lassen, Ulrik
Nilsson, Anna
Nysom, Karsten
Spano, Jean-Philippine
Norenberg, Ricarda
Bernard-Gauthier, Vadim
de la Cuesta, Esther
Drilon, Alexander
Laetsch, Theodore
van Tilburg, Cornelis
NEURO-ONCOLOGY, 2023, 25

← 1 2 3 4 5 →